GA regulated EMT to attenuate BLM-induced pulmonary fibrosis by inhibiting CF modification of key receptor proteins TGF-βRI, TGF-βRII, and WNT in the TGF-β/Smad2/3 and WNT/β-catenin signaling pathway. The gene discussed is TGFB1; the disease is pulmonary fibrosis.